Measuring and interpreting the selectivity of protein kinase inhibitors

Journal of Chemical Biology

Volumn 2, Issue 3, 2009, Pages 131-151

  Smyth, Lynette A ^a   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Polypharmacology; Protein kinase; Selectivity; Specificity

Indexed keywords

BMI 1026; BOSUTINIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; METHOTREXATE; NILOTINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PURVALANOL B; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 68949147006     PISSN: 18646158     EISSN: 18646166     Source Type: Journal    
DOI: 10.1007/s12154-009-0023-9     Document Type: Review

References (149)

1. I Akritopoulou-Zanze PJ Hajduk 2009 Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors Drug Discov Today 14 5-6 291 297
2. MD Allen LM DiPilato M Rahdar YR Ren C Chong JO Liu J Zhang 2006 Reading dynamic kinase activity in Living cells for high-throughput screening ACS Chem Biol 1 6 371 376
3. CB Andersen Y Wan JW Chang B Riggs C Lee Y Liu F Sessa F Villa N Kwiatkowski M Suzuki L Nallan R Heald A Musacchio NS Gray 2008 Discovery of selective aminothiazole Aurora kinase inhibitors ACS Chem Biol 3 3 180 192
4. K Aoki E Kiyokawa T Nakamura M Matsuda 2008 Visualization of growth signal transduction cascades in living cells with genetically encoded probes based on Forster resonance energy transfer Philos Trans R Soc B 363 1500 2143 2151
5. B Apsel JA Blair B Gonzalez TM Nazif ME Feldman B Aizenstein R Hoffman RL Williams KM Shokat ZA Knight 2008 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Nat Chem Biol 4 11 691 699
6. KL Arienti A Brunmark FU Axe K Mcclure A Lee J Blevitt DK Neff L Huang S Crawford CR Pandit L Karlsson JG Breitenbucher 2005 Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles J Med Chem 48 1873 1885
7. AM Aronov GW Bemis 2004 A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors Proteins 57 1 36 50
8. AM Aronov B McClain C Stuver Moody MA Murcko 2008 Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology J Med Chem 51 5 1214 1222
9. AM Aronov MA Murcko 2004 Toward a pharmacophore for kinase frequent hitters J Med Chem 47 23 5616 5619
10. MA Arslan O Kutuk H Basaga 2006 Protein kinases as drug targets in cancer Curr Cancer Drug Targets 6 7 623 634
11. Bach S, Blondel M, Meijer L (2007) Evaluation of CDK inhibitor selectivity: from affinity chromatography to yeast genetics. In: Smith P, Yue E (eds) Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents. CRC, New York, pp 103-119
12. S Bach M Knockaert J Reinhardt O Lozach S Schmitt B Baratte M Koken SP Coburn L Tang T Jiang L D-C H Galons J-F Dierick LA Pinna F Meggio F Totzke C Schaechtele AS Lerman A Carnero Y Wan N Gray L Meijer 2005 Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 35 31208 31219
13. J Bain H McLauchlan M Elliott P Cohen 2003 The specificities of protein kinase inhibitors: an update Biochem J 371 1 199 204
14. J Bain L Plater M Elliott N Shpiro CJ Hastie H McLauchlan I Klevernic JSC Arthur DR Alessi P Cohen 2007 The selectivity of protein kinase inhibitors: a further update Biochem J 408 3 297 315
15. P Bamborough D Drewry G Harper GK Smith K Schneider 2008 Assessment of chemical coverage of kinome space and its implications for kinase drug discovery J Med Chem 51 24 7898 7914
16. M Bantscheff D Eberhard Y Abraham S Bastuck M Boesche S Hobson T Mathieson J Perrin M Raida C Rau V Reader G Sweetman A Bauer T Bouwmeester C Hopf U Kruse G Neubauer N Ramsden J Rick B Kuster G Drewes 2007 Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat Biotechnol 25 9 1035 1044
17. SF Barnett D Defeo-Jones S Fu PJ Hancock KM Haskell RE Jones JA Kahana AM Kral K Leander LL Lee J Malinowski EM McAvoy DD Nahas RG Robinson HE Huber 2005 Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors Biochem J 385 2 399 408
18. JR Beasley PM McCoy TL Walker DA Dunn 2004 Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays Assay Drug Dev Technol 2 2 141 151
19. F Becker K Murthi C Smith J Come N Costa-Roldan C Kaufmann U Hanke C Degenhart S Baumann W Wallner A Huber S Dedier S Dill D Kinsman M Hediger N Bockovich S Meier-Ewert AF Kluge N Kley 2004 A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors Chem Biol 11 2 211 223 (Pubitemid 38300291)
20. B Bilanges N Torbett B Vanhaesebroeck 2008 Killing two kinase families with one stone Nat Chem Biol 4 11 648 649
21. V Birault CJ Harris J Le M Lipkin R Nerella A Stevens 2006 Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits Curr Med Chem 13 15 1735 1748
22. G Blum A Gazit A Levitzki 2000 Substrate competitive inhibitors of IGF-1 receptor kinase Biochemistry 39 51 15705 15712
23. MA Bogoyevitch DP Fairlie 2007 A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding Drug Discov Today 12 15&16 622 633
24. A Breda LA Basso DS Santos WF de Azevedo Jr 2008 Virtual screening of drugs: score functions, docking, and drug design Curr Comput-Aided Drug Des 4 4 265 272
25. S Burns J Travers I Collins MG Rowlands Y Newbatt N Thompson MD Garrett P Workman W Aherne 2006 Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreen high-throughput screen J Biomol Screen 11 7 822 827
26. Caffrey DR, Lunney EA, Moshinsky DJ (2008) Prediction of specificity-determining residues for small-molecule kinase inhibitors. BMC Bioinf. 9
27. JJ Caldwell TG Davies A Donald T McHardy MG Rowlands GW Aherne LK Hunter K Taylor R Ruddle FI Raynaud M Verdonk P Workman MD Garrett I Collins 2008 Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2, 3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration J Med Chem 51 7 2147 2157
28. V Calleja M Laguerre J Parker Peter B Larijani 2009 Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition PLoS Biol 7 1 e17
29. A Card C Caldwell H Min B Lokchander X Hualin S Sciabola V Kamath Ajith L Clugston Susan R Tschantz William W Leyu J Moshinsky Deborah 2009 High-throughput biochemical kinase selectivity assays: panel development and screening applications J Biomol Screen 14 1 31 42
30. PR Caron MD Mullican RD Mashal KP Wilson MS Su MA Murcko 2001 Chemogenomic approaches to drug discovery Curr Opin Chem Biol 5 4 464 470
31. G Castanedo K Clark S Wang V Tsui M Wong J Nicholas D Wickramasinghe JJC Marsters D Sutherlin 2006 CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads Bioorg Med Chem Lett 16 6 1716 1720
32. R Chaisuparat J Hu BC Jham ZA Knight KM Shokat S Montaner 2008 Dual inhibition of PI3K alpha and mTOR as an alternative treatment for Kaposi's Sarcoma Cancer Res 68 20 8361 8368
33. Z Chen FY Lee KN Bhalla J Wu 2006 Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib) Mol Pharmacol 69 5 1527 1533
34. Y-C Cheng WH Prusoff 1973 Relation between the inhibition constant (Ki) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction Biochem Pharmacol 22 23 3099 3108
35. M Cherry DH Williams 2004 Recent kinase and kinase inhibitor x-ray structures: mechanisms of inhibition and selectivity insights Curr Med Chem 11 6 663 673
36. JG Christensen 2007 A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities Ann Oncol 18 Suppl 10 x3 10
37. P Cohen 2002 Timeline: protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 1 4 309 315
38. P Cohen 2009 Targeting protein kinases for the development of anti-inflammatory drugs Curr Opin Cell Biol 21 2 317 324
39. I Collins MD Garrett 2005 Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors Curr Opin Pharmacol 5 4 366 373
40. I Collins P Workman 2006 Design and development of signal transduction inhibitors for cancer treatment: experience and challenges with kinase targets Curr Signal Transduction Ther 1 1 13 23
41. A Converso T Hartingh RM Garbaccio E Tasber K Rickert ME Fraley Y Yan C Kreatsoulas S Stirdivant B Drakas ES Walsh K Hamilton CA Buser X Mao MT Abrams SC Beck W Tao R Lobell L Sepp-Lorenzino J Zugay-Murphy V Sardana SK Munshi SM Jezequel-Sur PD Zuck GD Hartman 2009 Development of thioquinazolinones, allosteric Chk1 kinase inhibitors Bioorg Med Chem Lett 19 4 1240 1244
42. R Dandu AL Zulli ER Bacon T Underiner C Robinson H Chang S Miknyoczki J Grobelny BA Ruggeri S Yang MS Albom TS Angeles LD Aimone RL Hudkins 2008 Design and synthesis of dihydroindazolo[5, 4-a]pyrrolo[3, 4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases Bioorg Med Chem Lett 18 6 1916 1921
43. SL Davies J Bolos N Serradell M Bayes 2007 Nilotinib Drugs Future 32 1 17 25
44. SP Davies H Reddy M Caivano P Cohen 2000 Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 1 95 105
45. TG Davies ML Verdonk B Graham S Saalau-Bethell CCF Hamlett T McHardy I Collins MD Garrett P Workman SJ Woodhead H Jhoti D Barford 2007 A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB Chimera J Mol Biol 367 3 882 894
46. MJA de Jonge J Verweij 2006 Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? Eur J Cancer 42 10 1351 1356
47. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts MC Heinrich DA Tuveson S Singer M Janicek JA Fletcher SG Silverman SL Silberman R Capdeville B Kiese B Peng S Dimitrijevic BJ Druker C Corless CDM Fletcher H Joensuu 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 472 480
48. JJ Diaz-Mochon G Tourniaire M Bradley 2007 Microarray platforms for enzymatic and cell-based assays Chem Soc Rev 36 3 449 457
49. J Dunne H Reardon V Trinh E Li J Farinas 2004 Comparison of on-chip and off-chip microfluidic kinase assay formats Assay Drug Dev Technol 2 2 121 129
50. MA Fabian WH Biggs DK Treiber CE Atteridge MD Azimioara MG Benedetti TA Carter P Ciceri PT Edeen M Floyd JM Ford M Galvin JL Gerlach RM Grotzfeld S Herrgard DE Insko MA Insko AG Lai J-M Lelias SA Mehta ZV Milanov AM Velasco LM Wodicka HK Patel PP Zarrinkar DJ Lockhart 2005 A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 3 329 336
51. Q-W Fan ZA Knight DD Goldenberg W Yu KE Mostov D Stokoe KM Shokat WA Weiss 2006 A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 9 5 341 349
52. O Fedorov B Marsden V Pogacic P Rellos S Mueller AN Bullock J Schwaller M Sundstroem S Knapp 2007 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proc Natl Acad Sci U S A 104 51 20523 20528
53. O Fedorov M Sundstroem B Marsden S Knapp 2007 Insights for the development of specific kinase inhibitors by targeted structural genomics Drug Discov Today 12 9&10 365 372
54. A Fernandez A Sanguino Z Peng E Ozturk J Chen A Crespo S Wulf A Shavrin C Qin J Ma J Trent Y Lin H-D Han LS Mangala JA Bankson J Gelovani A Samarel W Bornmann AK Sood G Lopez-Berestein 2007 An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic J Clin Invest 117 12 4044 4054
55. PM Fischer 2004 The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases Curr Med Chem 11 12 1563 1583
56. JA Fletcher BP Rubin 2007 KIT Mutations in GIST Curr Opin Genet Dev 17 1 3 7
57. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 5 332 344 (Pubitemid 46652481)
58. AK Ghose T Herbertz DA Pippin JM Salvino JP Mallamo 2008 Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery J Med Chem 51 17 5149 5171
59. MP Gleeson 2008 Generation of a set of simple, interpretable ADMET rules of thumb J Med Chem 51 4 817 834
60. K Godl OJ Gruss J Eickhoff J Wissing S Blencke M Weber H Degen D Brehmer L Orfi Z Horvath G Keri S Mueller M Cotten A Ullrich H Daub 2005 Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling Cancer Res 65 15 6919 6926
61. DM Goldstein NS Gray PP Zarrinkar 2008 High-throughput kinase profiling as a platform for drug discovery Nat Rev Drug Discov 7 5 391 397
62. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao CL Sawyers 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 5531 876 880
63. PP Graczyk 2007 Gini Coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases J Med Chem 50 23 5773 5779
64. FM Gribble G Loussouarn SJ Tucker C Zhao CG Nichols FM Ashcroft 2000 A novel method for measurement of submembrane ATP concentration J Biol Chem 275 39 30046 30049
65. P Gribbon A Sewing 2003 Fluorescence readouts in HTS: no gain without pain? Drug Discov Today 8 22 1035 1043
66. CJ Harris AP Stevens 2006 Chemogenomics: structuring the drug discovery process to gene families Drug Discov Today 11 19-20 880 888
67. S Guillard PA Clarke R Te Poele Z Mohri L Bjerke M Valenti F Raynaud SA Eccles P Workman 2009 Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma Cell Cycle 8 3 443 453
68. BB Hasinoff D Patel KA O'Hara 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib Mol Pharmacol 74 6 1722 1728
69. CJ Hastie J McLauchlan Hilary P Cohen 2006 Assay of protein kinases using radiolabeled ATP: a protocol Nat Protoc 1 2 968 971
70. RJ Hill K Dabbagh D Phippard C Li RT Suttmann M Welch E Papp KW Song C K-C D Leaffer Y-N Kim RT Roberts TS Zabka D Aud J Dal Porto AM Manning SL Peng DM Goldstein BR Wong 2008 Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity J Pharmacol Exp Ther 327 3 610 619
71. AL Hopkins JS Mason JP Overington 2006 Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16 1 127 136
72. KY Horiuchi Y Wang SL Diamond H Ma 2006 Microarrays for the functional analysis of the chemical-kinase interactome J Biomol Screen 11 1 48 56
73. SR Hubbard JH Till 2000 Protein tyrosine kinase structure and function Annu Rev Biochem 69 373 398
74. GH Iyer P Taslimi S Pazhanisamy 2008 Staurosporine-based binding assay for testing the affinity of compounds to protein kinases Anal Biochem 373 2 197 206
75. LN Johnson MEM Noble DJ Owen 1996 Active and inactive protein kinases: structural basis for regulation Cell 85 2 149 158
76. M Johnson C Li B Rasnow P Grandsard H Xing A Fields 2002 Converting a protease assay to a Caliper® format LabChip system JALA 7 4 62 68
77. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell KW Chan P Ciceri MI Davis PT Edeen R Faraoni M Floyd JP Hunt DJ Lockhart ZV Milanov MJ Morrison G Pallares HK Patel S Pritchard LM Wodicka PP Zarrinkar 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 1 127 132
78. MA Kashem RM Nelson JD Yingling SS Pullen AS Prokopowicz III JW Jones JP Wolak GR Rogers MM Morelock RJ Snow CA Homon S Jakes 2007 Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors J Biomol Screen 12 1 70 83
79. SL Kinnings RM Jackson 2009 Binding site similarity analysis for the functional classification of the protein kinase family J Chem Inf Model 49 2 318 329
80. BM Klebl G Mueller 2005 Second-generation kinase inhibitors Expert Opin Ther Targets 9 5 975 993
81. ZA Knight KM Shokat 2005 Features of selective kinase inhibitors Chem Biol 12 6 621 637
82. DR Knighton J Zheng LF Ten Eyck VA Ashford X Nguyen Huu SS Taylor JM Sowadski 1991 Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 5018 407 414 (Pubitemid 21917165)
83. R Krishnamurty DJ Maly 2007 Chemical genomic and proteomic methods for determining kinase inhibitor selectivity Comb Chem High Throughput Screen 10 8 652 666
84. M Krug A Hilgeroth 2008 Recent advances in the development of multi-kinase inhibitors Mini-Rev Med Chem 8 13 1312 1327
85. C Kung DM Kenski SH Dickerson RW Howson LF Kuyper HD Madhani KM Shokat 2005 Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor Proc Natl Acad Sci U S A 102 10 3587 3592
86. C Kung DM Kenski K Krukenberg HD Madhani KM Shokat 2006 Selective kinase inhibition by exploiting differential pathway sensitivity Chem Biol 13 4 399 407
87. CS Lebakken HC Kang KW Vogel 2007 A fluorescence lifetime-based binding assay to characterize kinase inhibitors J Biomol Screen 12 6 828 841
88. Y-S Lee M Mrksich 2002 Protein chips, from concept to practice Trends Biotechnol 20 Suppl 12 S14 S18
89. B Li Y Liu T Uno N Gray 2004 Creating chemical diversity to target protein kinases Comb Chem High Throughput Screen 7 5 453 472
90. Y Li J Liang T Siu E Hu MA Rossi SF Barnett D Defeo-Jones RE Jones RG Robinson K Leander HE Huber S Mittal N Cosford P Prasit 2009 Allosteric inhibitors of Akt1 and Akt2: discovery of [1, 2, 4]triazolo[3, 4-f][1, 6]naphthyridines with potent and balanced activity Bioorg Med Chem Lett 19 3 834 836
91. JJ-L Liao 2007 Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J Med Chem 50 3 409 424
92. X Lin JM Murray AC Rico MX Wang DT Chu Y Zhou MD Rosario S Kaufman S Ma E Fang K Crawford AB Jefferson 2006 Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies Bioorg Med Chem Lett 16 16 4163 4168
93. CW Lindsley Z Zhao WH Leister RG Robinson SF Barnett D Defeo-Jones RE Jones GD Hartman JR Huff HE Huber ME Duggan 2005 Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorg Med Chem Lett 15 3 761 764
94. Y Liu NS Gray 2006 Rational design of inhibitors that bind to inactive kinase conformations Nat Chem Biol 2 7 358 364
95. LJ Lombardo FY Lee P Chen D Norris JC Barrish K Behnia S Castaneda LAM Cornelius J Das AM Doweyko C Fairchild JT Hunt I Inigo K Johnston A Kamath D Kan H Klei P Marathe S Pang R Peterson S Pitt GL Schieven RJ Schmidt J Tokarski M-L Wen J Wityak RM Borzilleri 2004 Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6- (4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 27 6658 6661
96. A Lueking DJ Cahill S Müllner 2005 Protein biochips: a new and versatile platform technology for molecular medicine Drug Discov Today 10 11 789 794
97. H Ma S Deacon K Horiuchi 2008 The challenge of selecting protein kinase assays for lead discovery optimization Expert Opin Drug Discov 3 6 607 621
98. H Ma KY Horiuchi 2006 Chemical microarray: a new tool for drug screening and discovery Drug Discov Today 11 13-14 661 668
99. 50 profiling Assay Drug Dev Technol 3 2 177 187
100. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600): 1912-1916, 1933-1934
101. BD Marsden S Knapp 2008 Doing more than just the structure-structural genomics in kinase drug discovery Curr Opin Chem Biol 12 1 40 45
102. MJ McGregor 2007 A pharmacophore map of small molecule protein kinase inhibitors J Chem Inf Model 47 6 2374 2382
103. JS Melnick J Janes S Kim JY Chang DG Sipes D Gunderson L Jarnes JT Matzen ME Garcia TL Hood R Beigi G Xia RA Harig H Asatryan SF Yan Y Zhou X-J Gu A Saadat V Zhou FJ King CM Shaw AI Su R Downs NS Gray PG Schultz M Warmuth JS Caldwell 2006 An efficient rapid system for profiling the cellular activities of molecular libraries Proc Natl Acad Sci U S A 103 9 3153 3158
104. MEM Noble JA Endicott LN Johnson 2004 Protein kinase inhibitors: insights into drug design from structure Science 303 5665 1800 1805
105. T O'Hare DK Walters EP Stoffregen T Jia PW Manley J Mestan SW Cowan-Jacob FY Lee MC Heinrich MWN Deininger BJ Druker 2005 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 11 4500 4505
106. B Okram A Nagle FJ Adrian C Lee P Ren X Wang T Sim Y Xie X Wang G Xia G Spraggon M Warmuth Y Liu NS Gray 2006 A general strategy for creating "inactive-conformation" Abl inhibitors Chem Biol 13 7 779 786
107. DM Olive 2004 Quantitative methods for the analysis of protein phosphorylation in drug development Expert Rev Proteomics 1 3 327 341
108. KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig J Baselga N Rosen 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 3 1500 1508
109. MA Pagano J Bain Z Kazimierczuk S Sarno M Ruzzene G Di Maira M Elliott A Orzeszko G Cozza F Meggio LA Pinna 2008 The selectivity of inhibitors of protein kinase CK2: an update Biochem J 415 3 353 365
110. S Park N Chapuis V Bardet J Tamburini N Gallay L Willems ZA Knight KM Shokat N Azar F Viguie N Ifrah F Dreyfus P Mayeux C Lacombe D Bouscary 2008 PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML Leukemia 22 9 1698 1706
111. MP Patricelli AK Szardenings M Liyanage TK Nomanbhoy M Wu H Weissig A Aban D Chun S Tanner JW Kozarich 2007 Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 46 2 350 358
112. MK Paul AK Mukhopadhyay 2004 Tyrosine kinase - role and significance in cancer Int J Med Sci 1 2 101 115
113. ML Peach N Tan SJ Choyke A Giubellino G Athauda TR Burke Jr MC Nicklaus DP Bottaro 2009 Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening J Med Chem 52 4 943 951
114. C Peifer A Krasowski N Haemmerle O Kohlbacher G Dannhardt F Totzke C Schaechtele S Laufer 2006 Profile and molecular modeling of 3-(indole-3-yl)-4- (3, 4, 5-trimethoxyphenyl)-1 H-pyrrole-2, 5-dione (I) as a highly selective VEGF-R2/3 iInhibitor J Med Chem 49 25 7549 7553
115. D Perrin C Fremaux A Scheer 2006 Assay development and screening of a serine/threonine kinase in an on-chip mode using caliper nanofluidics technology J Biomol Screen 11 4 359 368
116. A Petrelli S Giordano 2008 From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage Curr Med Chem 15 5 422 432
117. KG Petrov Y-M Zhang M Carter GS Cockerill S Dickerson CA Gauthier Y Guo RA Mook DW Rusnak AL Walker ER Wood KE Lackey 2006 Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series Bioorg Med Chem Lett 16 17 4686 4691
118. FI Raynaud S Eccles PA Clarke A Hayes B Nutley S Alix A Henley F Di-Stefano Z Ahmad S Guillard LM Bjerke L Kelland M Valenti L Patterson S Gowan A de Haven Brandon M Hayakawa H Kaizawa T Koizumi T Ohishi S Patel N Saghir P Parker M Waterfield P Workman 2007 Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases Cancer Res 67 5840 5850
119. TR Rheault TR Caferro SH Dickerson KH Donaldson MD Gaul AS Goetz RJ Mullin OB McDonald KG Petrov DW Rusnak LM Shewchuk GM Spehar AT Truesdale DE Vanderwall ER Wood DE Uehling 2009 Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors Bioorg Med Chem Lett 19 3 817 820
120. SM Rodems BD Hamman C Lin J Zhao S Shah D Heidary L Makings JH Stack BA Pollok 2002 A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases Assay Drug Dev Technol 1 1 Pt 1 9 19
121. H Ross CG Armstrong P Cohen 2002 A non-radioactive method for the assay of many serine/threonine-specific protein kinases Biochem J 366 3 977 981
122. PL Ross YN Huang JN Marchese B Williamson K Parker S Hattan N Khainovski S Pillai S Dey S Daniels S Purkayastha P Juhasz S Martin M Bartlet-Jones F He A Jacobson DJ Pappin 2004 Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents Mol Cell Proteomics 3 12 1154 1169
123. DW Rusnak K Affleck SG Cockerill C Stubberfield R Harris M Page KJ Smith SB Guntrip MC Carter RJ Shaw A Jowett J Stables P Topley ER Wood PS Brignola SH Kadwell BR Reep RJ Mullin KJ Alligood BR Keith RM Crosby DM Murray WB Knight TM Gilmer K Lackey 2001 The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res 61 19 7196 7203
124. G Scapin 2006 Protein kinase inhibition: different approaches to selective inhibitor design Curr Drug Targets 7 11 1443 1454
125. S Sciabola RV Stanton S Wittkopp S Wildman D Moshinsky S Potluri H Xi 2008 Predicting kinase selectivity profiles using Free-Wilson QSAR analysis J Chem Inf Model 48 9 1851 1867
126. Y-S Seong C Min L Li JY Yang S-Y Kim X Cao K Kim SH Yuspa H-H Chung KS Lee 2003 Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026 Cancer Res 63 7384 7391
127. FB Sheinerman E Giraud A Laoui 2005 High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding J Mol Biol 352 5 1134 1156
128. MA Sills D Weiss Q Pham R Schweitzer X Wu JJ Wu 2002 Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening J Biomol Screen 7 3 191 214
129. JJ Slon-Usakiewicz J-R Dai W Ng JE Foster E Deretey L Toledo-Sherman PR Redden A Pasternak N Reid 2005 Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery Anal Chem 77 5 1268 1274
130. JB Smaill EN Baker RJ Booth AJ Bridges JM Dickson EM Dobrusin I Ivanovic AJ Kraker HH Lee EA Lunney DF Ortwine BD Palmer J Quin III CJ Squire AM Thompson WA Denny 2008 Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3, 4-c]carbazole-1, 3(2H, 6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases Eur J Med Chem 43 6 1276 1296
131. Smyth LA, Matthews TP, Collins I (2009) Kinase-directed libraries inspired by the natural product Indirubin. Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, Mar. 22-26, 2009: ORGN - 352
132. S Soverini S Colarossi A Gnani G Rosti F Castagnetti A Poerio I Iacobucci M Amabile E Abruzzese E Orlandi F Radaelli F Ciccone M Tiribelli R di Lorenzo C Caracciolo B Izzo F Pane G Saglio M Baccarani G Martinelli 2006 Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive Patients: by the GIMEMA working party on chronic myeloid leukemia Clin Cancer Res 12 24 7374 7379
133. Taylor RD, Bailey S. "Small molecule oral kinase inhibitor in oncology - UCB datasheet." from www.ucb-group.com
134. H Tecle J Shao Y Li M Kothe S Kazmirski J Penzotti Y-H Ding J Ohren D Moshinsky R Coli N Jhawar E Bora S Jacques-O'Hagan J Wu 2009 Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK? Bioorg Med Chem Lett 19 1 226 229
135. TW Traut 1994 Physiological concentrations of purines and pyrimidines Mol Cell Biochem 140 1 1 22
136. P Traxler P Furet 1999 Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacol Ther 82 2-3 195 206
137. BE Turk 2005 Measuring kinase activity: finding needles in a haystack Nat Methods 2 4 251 252
138. M Vieth JJ Sutherland DH Robertson RM Campbell 2005 Kinomics: characterizing the therapeutically validated kinase space Drug Discov Today 10 12 839 846
139. AG Waterson KG Petrov KR Hornberger RD Hubbard DM Sammond SC Smith HD Dickson TR Caferro KW Hinkle KL Stevens SH Dickerson DW Rusnak GM Spehar ER Wood RJ Griffin DE Uehling 2009 Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors Bioorg Med Chem Lett 19 5 1332 1336
140. S Wilhelm C Carter M Lynch T Lowinger J Dumas RA Smith B Schwartz R Simantov S Kelley 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 10 835 844
141. SM Wilhelm L Adnane P Newell A Villanueva JM Llovet M Lynch 2008 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 10 3129 3140
142. W Xia RJ Mullin BR Keith L-H Liu H Ma DW Rusnak G Owens KJ Alligood NL Spector 2002 Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 21 41 6255 6263
143. J Zhang PL Yang NS Gray 2009 Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 1 28 39
144. X Zhang A Crespo A Fernandez 2008 Turning promiscuous kinase inhibitors into safer drugs Trends Biotechnol 26 6 295 301
145. Z Zhang KE Meier 2006 New assignments for multitasking signal transduction inhibitors Mol Pharmacol 69 5 1510 1512
146. H Zhu M Snyder 2003 Protein chip technology Curr Opin Chem Biol 7 1 55 63
147. LR Zieske 2006 A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies J Exp Bot 57 7 1501 1508
148. C Peifer R Urich V Schattel M Abadleh M Roettig O Kohlbacher S Laufer 2008 Implications for selectivity of 3,4- diarylquinolinones as p38alpha MAP kinase inhibitors Bioorg Med Chem Lett 18 4 1431 1435
149. D Brechmer Z Greff K Godl S Blencke A Kurtenbach M Weber S Mueller B Klebl M Cotten G Keri J Wissing H Daub 2005 Cellular targets of gefitinib Cancer Res 57 7 1501 1508